GlaxoSmithKline plc Earnings Recaps
Q3 2025
Oct 29, 2025
GSK delivered robust Q3 results, with total sales rising 8% and core earnings per share increasing 14% to 55p, prompting an upward revision of its full-year guidance.
Key takeaways
- Specialty medicines revenue surged 16% driven by strong performances in RI&I, oncology, and HIV.
- GSK secured four FDA approvals in 2025, bolstering its late-stage pipeline.
- Cash generation remains strong at £6.3 billion YTD, supporting investments and a quarterly dividend of 16p.
- The strengthened balance sheet and ongoing operational improvements have allowed for an upgrade in long-term sales outlook to over £40 billion by 2031.
- Significant R&D investment of $30 billion planned over the next five years, including construction of a new biologics facility in Pennsylvania.
Q2 2025
Aug 1, 2025
GSK reported a robust Q2 2025 performance, with group sales up 6% and core operating profit increasing 12%, bolstered by strong contributions from Specialty Medicines and vaccines.
Key takeaways
- Specialty Medicines drove a significant 15% sales growth, now accounting for 40% of total sales.
- Core earnings per share grew 15% to 46.5p, reflecting strong operational execution and effective cost management.
- GSK generated GBP 3.7 billion in cash in H1 2025, supporting shareholder returns and ongoing investments in R&D and pipeline expansion.
- The company remains on track to achieve top-end guidance for 2025 and projects long-term sales exceeding GBP 40 billion by 2031.
- Positive advancements in R&D, with three FDA approvals year-to-date, enabling accelerated pipeline development in specialty therapies.